24 completed, 9 unknown, 6 terminated, 2 not yet recruiting. 45 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 45 | Completed 24, Unknown 9, Terminated 6, Not yet recruiting 2, Withdrawn 2, Active not recruiting 1, Recruiting 1 |
Follow Myeloproliferative Disorders: new trials by email Literature Review of Myeloproliferative Disorders trials Research Report on Myeloproliferative Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts Momelotinib, Ruxolitinib - Myelofibrosis, Myelofibrosis (MF) | Phase 4 | Not yet recruiting | SWOG Cancer Research Network | 268 | 2026-11-01 | 2026-09-17 |
| Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera Ropeginterferon alfa-2b, Phlebotomy and aspirin - Polycythemia Vera, Myeloproliferative Neoplasm | Phase 4 | Withdrawn | PharmaEssentia | 2026-08-01 | 2026-07-31 | |
| Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation Asciminib - Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase | Phase 4 | Completed | Novartis Pharmaceuticals | 85 | 2024-11-28 | 2026-06-08 |
| Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors Hydroxyurea - Polycythemia Vera | Phase 4 | Terminated | Novartis Pharmaceuticals | 76 | 2023-07-28 | 2026-08-18 |
| Asciminib Roll-over Study Asciminib single agent, Imatinib, Nilotinib - Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Phase 4 | Recruiting | Novartis Pharmaceuticals | 347 | 2022-08-30 | 2026-11-09 |
| A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis Ruxolitinib - Myelofibrosis | Phase 4 | Unknown | Qilu Hospital of Shandong University | 87 | 2022-06-10 | 2022-07-07 |
| A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Flumatinib, Imatinib - CML, Chronic Phase | Phase 4 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2400 | 2022-04-30 | 2022-05-10 |
| Ropeginterferon for Treatment Free Remission Ropeginterferon - CML (Chronic Myelogenous Leukemia) | Phase 4 | Completed | Dong-Wook Kim | 65 | 2021-11-30 | 2025-08-22 |
| A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. Flumatinib mesylate tablets (400mg), Flumatinib mesylate tablets (600mg) - CML, Chronic Phase | Phase 4 | Unknown | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 200 | 2021-11-23 | 2022-04-29 |
| Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure Flumatinib - Flumatinib, Chronic Myeloid Leukemia, Chronic Phase | Phase 4 | Unknown | Shenzhen Second People's Hospital | 200 | 2021-01-01 | 2022-03-16 |
| Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP Dasatinib - Dasatinib, BCR-ABL | Phase 4 | Unknown | Shenzhen Second People's Hospital | 65 | 2019-12-01 | 2022-07-27 |
| Anagre Cap. in Patients With High-Risk Essential Thrombocythemia Anagre Cap. - Essential Thrombocythemia | Phase 4 | Completed | Yuhan Corporation | 70 | 2017-06-05 | 2021-07-21 |
| Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia Imatinib, Nilotinib - Chronyc Myeloid Leukemia | Phase 4 | Unknown | Gruppo Italiano Malattie EMatologiche dell'Adulto | 450 | 2016-11-11 | 2022-01-20 |
| A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Dasatinib Tablets - Chronic Myelogenous Leukemia - Chronic Phase | Phase 4 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 62 | 2016-05-10 | 2021-06-14 |
| Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia Dasatinib 50 MG - Chronic Myelogenous Leukemia | Phase 4 | Unknown | Hospital Universitario Dr. Jose E. Gonzalez | 12 | 2016-04-01 | 2017-07-13 |
| Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline. Nilotinib - Chronic Myeloid Leukemia | Phase 4 | Completed | Novartis Pharmaceuticals | 171 | 2016-02-18 | 2022-07-22 |
| Multicenter, Phaseâ…£, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib Nilotinib - Leukemia, Chronic Myeloid | Phase 4 | Unknown | Samsung Medical Center | 40 | 2015-04-01 | 2015-03-17 |
| CINC424A2X01B Rollover Protocol ruxolitinib, panobinostat - Primary Myelofibrosis, Polycythemia Vera | Phase 4 | Active not recruiting | Novartis Pharmaceuticals | 279 | 2015-03-05 | 2026-10-19 |
| Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia Imatinib - Chronic Myeloid Leukemia | Phase 4 | Unknown | Cttq | 90 | 2015-02-01 | 2014-12-15 |
| Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors Bosutinib - Previously Treated PH + CML | Phase 4 | Terminated | Pfizer | 163 | 2014-11-07 | 2021-12-30 |
Showing 20 of 45. Sign in to see all of them.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (29) · Leukemia, Myeloid, Chronic-Phase (8) · Leukemia (5) · Primary Myelofibrosis (4) · Blast Crisis (3) · Bronchiolitis Obliterans Syndrome (3) · Polycythemia Vera (3) · Thrombocythemia, Essential (3) · Gastrointestinal Stromal Tumors (2) · Graft vs Host Disease (2) · Leukemia, Myeloid, Acute (2) · Lymphoma (2) · Myelodysplastic Syndromes (2) · Neoplasms, Plasma Cell (2)
Hematologic Diseases (45) · Hemic and Lymphatic Diseases (45) · Bone Marrow Diseases (44) · Neoplasms (40) · Neoplasms by Histologic Type (38) · Leukemia, Myeloid (37) · Chronic Disease (36) · Disease Attributes (36) · Pathologic Processes (36) · Pathological Conditions, Signs and Symptoms (36) · Leukemia (33) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (7) · Immune System Diseases (6) · Neoplasms by Site (4)
nilotinib (14) · Imatinib Mesylate (11) · Dasatinib (5) · ruxolitinib (4) · Hydroxyurea (2) · asciminib (2) · bosutinib (2) · flumatinib (2) · Antilymphocyte Serum (1) · Aspirin (1) · Busulfan (1) · Cyclophosphamide (1) · Filgrastim (1) · Growth Hormone (1) · Interferons (1)
Novartis Pharmaceuticals (17) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (2) · Shenzhen Second People's Hospital (2) · Bristol-Myers Squibb (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Cttq (1) · Dong-A ST Co., Ltd. (1) · Dong-Wook Kim (1) · Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Hospital Universitario Dr. Jose E. Gonzalez (1) · King Abdullah International Medical Research Center (1) · PETHEMA Foundation (1) · Pfizer (1)
United States (11) · China (9) · France (8) · Germany (8) · Canada (7) · Italy (7) · South Korea (7) · Spain (6) · Poland (4) · United Kingdom (4) · Austria (3) · Brazil (3) · Bulgaria (3) · Hungary (3) · India (3)
Jun Ma (2) · Alessandra Iurlo, MD (1) · Alexander Coltoff, MD (1) · Andreas Hochhaus, Professor, MD (1) · Arnon Nagler, MD (1) · Barry R. Meisenberg, MD (1) · Bruno Martino, MD (1) · Carlo Gambacorti-Passerini, MD (1) · Cervantes Francisco, Dr (1) · Chul-won Choi, M.D. (1) · Chul-won Jung, M.D. (1) · Dr. Ahmad S. Alaskar, MD,FACP,FRCP (1)
PMID 19720924, PMID 20220063, PMID 21670449, PMID 22198540, PMID 25170123, PMID 26993758, PMID 27771544, PMID 29577674, PMID 30368038, PMID 30912699, PMID 32572189, PMID 33123978, PMID 35235189, PMID 38007586, PMID 38484432, PMID 39164407
2004 (1), 2014 (1), 2015 (1), 2023 (1)